[
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "23\n Figure 1 briefly depicts the mechanism of endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, the abnormal expression of receptor tyrosine kinase (RTK), EGFR, HER‐2, IGF‐1R, fibroblast growth factor receptors (FGF‐R) and abnormal activation such as PI3K/PTEN/AKT/mTOR signalling pathway, NF‐kB signalling pathway may be involved in drug resistance (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Tamoxifen treatment can increase the ability of YBX1 to bind to the HER‐2 promoter region, Induction of HER‐2 transcriptional activation and increased expression (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In support, the RET ligand GDNF has been shown to induce endocrine therapy resistance (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "At the same time, dual specificity phosphatase7 (DUSP7) is used as a negative regulator of ERK, which reduces the stability of DUSP7 through Linc‐RoR and activates the MAPK/ERK signalling pathway (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 6 demonstrates the mechanism of prolactin in endocrine resistance.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "PKB or AKT is an essential downstream molecule of PI3K, plays an essential role in regulating cell growth, proliferation, survival and glycose metabolism of cells and PI3K/AKT pathway can activate the downstream target protein mTOR (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Next, focal adhesion kinase (FAK) is required to mediate the strong adhesion of the extracellular matrix (Figure 8).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  }
]